Next Article in Journal
Glioblastoma Therapy: Past, Present and Future
Previous Article in Journal
Functional and Compositional Changes in Sirex noctilio Gut Microbiome in Different Habitats: Unraveling the Complexity of Invasive Adaptation
Previous Article in Special Issue
Novel Immortalized Human Multipotent Mesenchymal Stromal Cell Line for Studying Hormonal Signaling
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 25
Issue 5
10.3390/ijms25052527
Review Report
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Biology and Therapeutic Properties of Mesenchymal Stem Cells in Leukemia

Int. J. Mol. Sci. 2024, 25(5), 2527; https://doi.org/10.3390/ijms25052527
by Cheng-Hsien Wu 1,†, Te-Fu Weng 2,3,†, Ju-Pi Li 2,4,* and Kang-Hsi Wu 2,3,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2024, 25(5), 2527; https://doi.org/10.3390/ijms25052527
Submission received: 7 January 2024 / Revised: 8 February 2024 / Accepted: 15 February 2024 / Published: 21 February 2024
(This article belongs to the Special Issue Molecular Biology and Therapeutic Properties of Mesenchymal Stromal Cells)

Round 1

Reviewer 1 Report

Comments and Suggestions for Authors

Overall, a very good paper summarizing the MSC-HSC interactions in the BM niche. However, the "potential applications" section is the most important and requires significant development + critical analysis. 

MSCs in diseased tissue of leukemia are clearly very different from healthy MSCs obtained from the bone marrow or other sources. Are there any studies testing the utility of healthy MSCs within the cancerous BM-niche?

If so, could this be related to somehow the modification of MSCs within the bm niche? Also, how does the signature (i.e. immunomodulatory) differ between healthy and cancerous MSCs? 

Is there a way to test if early vs late onset leukemia affects MSCs first or HSCs first? Also, are there signals from HSCs are that are modifying the MSC immunophenotype? 

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

Comments and Suggestions for Authors

Wu and others did a beautiful job in comprehensively reviewing the biology and therapeutic properties of MSC in leukemia. The review is well organized and presented. I enjoyed the tables summarizing the roles of MSC in multiple types of leukemia. The manuscript is already good for publication. I only have a minor suggestion to improve the manuscript further:

1. The anti and pro-tumorigenic effects of MSC in AML are quite interesting. Further investigations might be important to translate the MSC-targeting therapy to clinical settings. It would be helpful if the authors could improve the table 1. Instead of laying out the experimental results, it could be better to categorize the "pro-tumorigenesis" and "anti-tumorigenesis", and summarize the reasons why distinct results were derived from different experimental settings. 

2. Figure 2 and Figure 3 legends were swapped. I believe Figure 2 is the clinic application and Figure 3 is the anti/pro-tumorigenesis effects. 

Overall, it is a quality review that can be helpful for the scientists in the field. 

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Back to TopTop